移至主內容

Transabdominal amnioinfusion for improving fetal outcomes after oligohydramnios secondary to preterm prelabour rupture of membranes before 26 weeks

Babies born after preterm prelabour rupture of membranes (PPROM) between 16 and 26 weeks of pregnancy are prone to underdevelopment of the lungs. When the membranes containing the fluid that surrounds the baby (amniotic fluid) rupture, a shortage of this fluid can occur, a condition that is called oligohydramnios. Oligohydramnios is thought to interfere with normal lung development so that it is delayed, resulting in a condition that is called pulmonary hypoplasia.

Pulmonary hypoplasia can present as severe breathing problems or as milder and even transient breathing problems. It can be accompanied by bleeding in the lung and can also result in chronic breathing problems due to scarring of lung tissue. There may also be neurological complications, fetal deformities and neonatal sepsis with oligohydramnios.

Replacement of fluid via a needle passed through the abdominal wall in the uterine cavity and into a pocket of amniotic fluid, (transabdominal amnioinfusion) under ultrasound guidance has been proposed to improve pregnancy outcome. Most clinical experience suggests that amnioinfusion is safe for both the mother and the baby, however, we did not identify any randomised trials of transabdominal amnioinfusion following PPROM before 26 weeks for inclusion in this review. Currently, there is no evidence to evaluate the use of transabdominal amnioinfusion in women with oligohydramnios following  rupture of fetal membranes before 26 weeks for improving birth outcomes.

背景

Preterm prelabour rupture of membranes (PPROM) before 26 weeks can delay lung development and can cause pulmonary hypoplasia, as a result of oligohydramnios. Restoring the amniotic fluid volume by transabdominal amnioinfusion might prevent abnormal lung development and might have a protective effect for neurological complications, fetal deformities and neonatal sepsis.

目的

To assess the effectiveness of transabdominal amnioinfusion in improving perinatal outcome in women with oligohydramnios secondary to rupture of fetal membranes before 26 weeks.

搜尋策略

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2013).

選擇標準

All randomised controlled trials comparing transabdominal amnioinfusion with no transabdominal amnioinfusion. Cluster- or quasi-randomised trials were not eligible for inclusion. In cases where only an abstract was available, we attempted to find the full articles.

資料收集與分析

Two review authors assessed trials for inclusion. No eligible trials were identified.

主要結果

There are no included studies.

作者結論

There is currently no evidence to evaluate the use of transabdominal amnioinfusion in women with oligohydramnios secondary to rupture of fetal membranes before 26 weeks for improving perinatal outcome. Further research examining the effects of this intervention is needed. Two randomised controlled trials are ongoing but final data have not yet been published.

引用文獻
Van Teeffelen S, Pajkrt E, Willekes C, Van Kuijk SMJ, Mol BWJ. Transabdominal amnioinfusion for improving fetal outcomes after oligohydramnios secondary to preterm prelabour rupture of membranes before 26 weeks. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD009952. DOI: 10.1002/14651858.CD009952.pub2.

我們對Cookie的使用

我們使用必要的 cookie 使我們的網站正常運作。我們還希望設置可選擇分析的 cookie,以幫助我們進行改進網站。除非您啟用它們,否則我們不會設置可選擇的 cookie。使用此工具將在您的設備上設置 cookie,以記住您的偏好。您隨時可以隨時通過點擊每個頁面下方的「Cookies 設置」連結來更改 Cookie 偏好。
有關我們使用 cookie 的更多詳細資訊,請參閱我們的 cookie 頁面

接受所有
配置